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INTRODUCTION
This thesis focuses on positron emission tomography, the cardiac blood flow,
the cardiac metabolism and their regulating mechanisms in relation to
pathological processes. For a better understanding, this introduction will
address the most important physiologic mechanisms of the cardiac blood
flow and the cardiac metabolism, and the pathophysiology in atherosclerosis.
PHYSIOLOGY OF THE CORONARY CIRCULATION
The coronary circulation consists of three different compartments. Although
their borders can not be distinguished exactly anatomically or histologically,
the three compartments differ in function. From the origin in the aorta we
discriminate consecutively the macrocirculation with epicardial conductive
vessels, and the microcirculation containing the prearteriolar, and the
arteriolar/capillary compartment.
Macrocirculation
The proximal compartment of the coronary circulation is represented by
the large epicardial conductance vessels which originate from the aorta
and extend to the entrance of the ventricular wall. Histologically epicardial
conductance vessels are characterized by a vessel wall to vessel lumen ratio
of 1:4 with a relatively large media of which 60% contains smooth muscle
cells. These smooth muscle cells control the vessel diameter and are
influenced by various stimuli.  Adjacent to the vessel lumen the intima is
lined with endothelial cells necessary to induce vasomotor responses via
the underlying smooth muscle cell layer. The adventitia marks the outer
border of the vessel and is characterized by sparse connection between
nerves and smooth muscle cells, indicating minimal neural control in this
compartment.
The most important functions of these vessels are to distribute the blood to
the myocardium and to increase capacity to store blood during systole. The
branching and tapering pattern of the proximal compartment enables the
distribution of blood to be carried out in an efficient way with minimal wall
shear stress and minimal loss of kinetic energy. The capacitance function is
illustrated by an increase of 25% in vessel volume during systole to store
the antegrade flow from the aorta and retrograde flow from the
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intramyocardial vessels. The volume increase enhances elastic energy in
the vessel wall which is converted into kinetic energy at the beginning the
diastole and contributes to the opening of the intramyocardial vessels that
have been squeezed during systole. Capacitance is also increased by beta
adrenergic stimulation, an important mechanism involved in response to
exercise. As the microcirculation provides most of the vascular resistance,
conductance vessels have only minimal impact (25%) on vessel resistance1,2.
Microcirculation
The most important function of the microcirculation is to regulate to coronary
vascular resistance and to respond to metabolic changes in the myocardium.
The latter function is mainly controlled in the arteriolae and capillaries,
whereas resistance is regulated predominantly in the prearteriolae.
However, both compartments demonstrate overlap in function, and
anatomical borders are not strictly separated. Anatomically and
histologically the prearteriolar compartment is not very much different from
the macrocirculation, except for a more dense innervation. Main function
of this compartment is to modulate resistance so that pressure at the origin
of the arteriolae can be maintained within a narrow range1.
The prearteriolae and arteriolae both provide resistance as illustrated in
experimental studies in cats: vessels with diameter greater than 170 µm
provided 25% of the resistance, vessels between 100-170 µm 25%, the venous
compartment 10%, thus leaving 40% of the resistance to vessels smaller
than 100µm2. Resistance is predominantly adjusted to changes in flow via
shear stress mediated release of endothelium derived relaxing factor, and
changes in pressure are followed by adjustment of the myogenic vessel tone.
The third and last compartment consists of the arteriolae and the capillaries.
Histologically arteriolae are characterized by a thick muscular vessel wall,
with a wall to lumen ratio of 2:3, and richly innervated. Main functions are
to provide resistance as mentioned previously and to adjust the blood flow
to the myocardial demand (described below).
Regulating mechanisms of the coronary circulation
The different mechanisms for the regulation of vasomotion control are not
equally important in the three components of the coronary circulation.
Metabolic regulation is predominantly present in the arteriolae, whereas
prearterioles and conduit arteries are mainly regulated by shear stress,
autonomic neural, and neurohumoral mechanisms.
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Metabolic regulation
Metabolic regulation is the most important regulating mechanism in the
arteriolae and the capillaries. Adjustment to the myocardial demand is
predominantly carried out via vasodilatation or vasoconstriction in response
to changes in the interstitial metabolite concentration, reflecting the
metabolic state of the myocardial cells. The sensitivity to adjust metabolic
changes depends on the wall thickness of the vessel. An increased wall
thickness impairs diffusion of metabolites and consequently the
vasodilatatory response is diminished. In the microcirculation vessels with
a diameter smaller than 100 µm appear the most critical section, because
they show the greatest vasodilatation in metabolic regulation3. When the
balance between myocardial demand and supply is shifted to higher demand,
the oxygen consumption increases. Consequently, tissue oxygen pressure
decreases, and the concentration of metabolites and tissue carbon dioxide
rises. This causes a concentration dependent increase in smooth muscle
cell relaxation, which induces an increase in coronary blood flow so that
equilibrium is reset at a higher flow level. For a decrease in myocardial
demand a reverse process takes place.
Shear stress regulation
Shear stress to the vessel wall (τ) is presumed the most important regulating
factor in the prearteriolae to changes in coronary flow and is characterized
by a formula which includes radius of the vessel lumen (r), flow through
the vessel (Q), and blood viscosity (η).
In formula: τ = 4 * η * Q
      pi * r3
To remain shear stress constant at a minimal level in a nonpathological
state, changes in flow are compensated by subsequent change in radius,
presuming a constant blood viscosity. Shear stress regulated changes are
prominent when flow in the proximal compartment increases due to a
vasodilatation in the distal compartment, initiated by for example an
increased metabolic demand.
Different degrees of shear stress mediated regulation exist in the coronary
artery tree. The endothelium in the epicardial conductance vessel responds
to shear stress, but most pronounced responses are observed in the
prearteriolae. Further descending the coronary artery tree, responsiveness
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to shear stress declines, as suggested by a more prominent shear stress
regulation in prearteriolae compared to the smaller arteriolae and
capillaries3.
Endothelium Derived Relaxing Factors
Among endothelium derived relaxing factors (EDRF), nitric oxide is
produced by endothelial cells in response to changes in shear stress in
nonpathological conditions. Nitric oxide diffuses from the endothelial cell
to the vascular smooth muscle cell where it stimulates cyclic-
guaninemonophosphate production causing relaxation of the smooth muscle
which in turn dilatates the vessel. In pathological conditions such as in
atherosclerosis where the endothelium is injured, nitric oxide mediated
vasomotor control may be decreased or lost resulting in an impaired
vasodilatation or even a paradoxical vasoconstriction to increased shear
stress and to exogenous stimulation of nitric oxide production with
acetylcholine4. Other factors that influence vasomotion are prostaglandin
and endothelium derived hyperpolarization factor, stimulating cyclic-
adenosinemonophosphate and increasing intracellular potassium
concentration respectively, resulting in smooth muscle relaxation and
dilatation of the vessel. Experimental data suggest that endothelium derived
relaxing factor production is greater in resistive vessels compared to
epicardial conduit vessels5
Autonomic neural regulation
The autonomic nervous system can be divided into a parasympathetic and
a sympathetic component. Concerning the parasympathetic component,
general opinion is that its involvement in regulation of the coronary
vasomotion is minimal. Vagal stimulation results in release of acetylcholine
in parasympathetic nerve endings, which appeared to have no direct- or
indirect effect on coronary vasomotion in an experimental setting in dogs6
In humans vasodilatation after infusion of exogenous acetylcholine was
demonstrated, however this vasodilatation seemed predominantly due to
the acetylcholine induced flow mediated changes in the coronary
microcirculation, rather than due to a direct parasympathetic effect4.
Activation of the sympathetic component causes stimulation of both alpha
and beta adrenoceptors. In an experimental setting direct beta adrenoceptor
stimulation causes vasodilatation in epicardial conduit arteries exerted by
stimulation of beta 1 adrenoceptors and by beta 2 adrenoceptors in resistive
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vessels7,8. Through beta adrenoceptor activation an increase in myocardial
inotropic and chronotropic state is obtained, which enables the myocardium
to meet the increased metabolic demand during exercise9. Direct stimulation
of alpha adrenoceptors by cardiac sympathetic nerves result in modest
coronary vasoconstriction and greater vasoconstrictive effects are exerted
by circulating catecholamines10. However, the exact mechanisms are not
yet elucidated, because alpha adrenoceptors may also be involved in feed-
back control mechanisms influencing vasodilatatory responses in exercise11.
Moreover, there is controversy whether alpha 1 and 2 adrenoceptors are
heterogeneously distributed in the coronary circulation2,12,13.
Neurohumoral regulation
Spillover fractions from cardiac terminal nerve endings constitute a major
source for circulating catecholamines. As previously mentioned the effect
of beta stimulation appears small, but circulating catecholamines exert a
significant alpha adrenergic constrictor effect14. In addition, there are other
vasoactive substances that may influence the coronary vasomotor tone like




metabolites ↑, pCO2 ↑, pO2 ↓ in myocardium
↓
metabolic mediated dilatation in arteriolae
↓
flow increase in arteriolae
↓
shear stress mediated dilatation prearteriolae
↓
flow increase in prearteriolae
↓
shear stress mediated dilatation conductance vessels
(to lesser extent than prearteriolae)
↓
flow increase in conductance vessels
↓
renewed equilibrium of flow relative to metabolic demand
Figure 1.
Dynamic myocardial perfusion model
The metabolic and shearstress regulating mechanisms are integrated in a dynamic hypothetical




Dynamic myocardial perfusion model
The metabolic and shearstress regulating mechanisms may be integrated
in a dynamic hypothetical system that specifically illustrates how the
myocardium may respond to an increased myocardial metabolic demand
for example during exercise3 (Figure 1). When myocardial demand decreases
a reverse process takes place. The changes in myocardial perfusion are
also modulated by the autonomic nervous system and neurohumoral stimuli,
but it is not exactly known where and how in this model the autonomic
nervous system and neurohumoral stimuli exert their effects.
PHYSIOLOGY OF THE CARDIAC METABOLISM
Under normal conditions fatty acids are the predominant fuel for cardiac
energy production15. Although cardiac glucose metabolism is of considerable
importance in ischemia, also in non-ischemic circumstances glucose
metabolism plays a role16.
Glucose for metabolism is taken up from the blood via GLUT-transporters
and transported into the cell17, or derived from intracellular stores of
glycogen. Eventually, both glucose and glycogen are converted to glucose-6-
phosphate and further to acetyl-CoA by different enzymes, whereafter acetyl-
CoA enters the Krebs-cycle for energy production in the form of
adenosinetriphosphate. Lactate may also provide the myocardial cell with
energy by conversion to acetyl-CoA via pyruvate, dependent on the lactate
concentration18.
Glucose as energy source for the myocardial cell is dependent on substrate
availability, the hormonal milieu and the amount of cardiac work. The use
of glucose or glycogen under normal conditions is inhibited by a high
concentration of fatty acids. Conversely, glucose is used as main energy
source when fatty acid concentrations are low and concentrations of glucose
and insulin are high, as in the post prandial state or during hyperinsulinemic
euglycemic glucose clamp technique19,20. Furthermore, various hormones
influence myocardial glucose metabolism: catecholamines increase glucose
uptake and glycogen breakdown21, insulin stimulates glucose uptake from
the blood via the GLUT1-4 transporters22, and other substances like
glucagon, thyroid hormone, bradykinin, cytokines, TNF-alpha also play a
role in the regulation of glucose metabolism. Finally, there exists a tight
coupling between cardiac work, coronary flow and substrate oxidation
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resulting in an increased glucose uptake and increased breakdown of
glycogen in response to an increased cardiac work23,24. This process also
modulated by elevated levels of catecholamines25. Central in the adaptation
to cardiac work appears to be an increase in calcium ions concentration,
possibly acting as an inciting stimulus.
PATHOPHYSIOLOGY OF ATHEROSCLEROSIS
Atherosclerosis is considered a generalized inflammation process in which
all compartments of the coronary artery tree may become involved. The
atherosclerotic process causes acute and chronic alterations in the
interaction between blood components and the vessel wall. Manifestations
of atherosclerosis range from endothelial dysfunction to the formation of
atherosclerotic plaques and may lead to symptoms in patients (Figure 2,
Chain of events in atherosclerosis). Atherosclerosis is considered a response
to injury by toxic substances, such as oxidized low density lipoproteins,
free radicals and probably even viral infections26.
Endothelial dysfunction and atherosclerotic plaques
Endothelial dysfunction is considered the earliest sign of atherosclerosis,
Figure 2.
The chain of events involved in coronary artery disease is associated with progressive endot-
helial dysfunction. This is symbolyzed by the partly unfolded blood vessel, in which only func-
tionally intact endothelial cells are displayed. (Reprinted with permission from J.H. Buikema.




and plays a role in the initiation and the progression of atherosclerosis. On
the other side of the spectrum is the formation of atherosclerotic plaques,
which are localized in the epicardial conductance vessels.
Both endothelial dysfunction and the formation of atherosclerotic plaques
are the result of a complex interaction between resident cells of the vessel
wall (endothelial cells and smooth muscle cells) and cells of the immune
system. Oxidized low density lipoprotein and free radicals are important
factors that damage the endothelium and promote atherosclerotic plaque
formation. When the endothelium is injured inappropriate regulation of
vasoactive substances may cause an impaired vasodilatation or even
paradoxical vasoconstriction in response to stress, to autonomic activation
or to infusion with acetylcholine. This reaction of the endothelium might
even cause myocardial ischemia27-30. Since endothelial function is the main
regulating mechanism in the coronary microcirculation, endothelial
dysfunction plays a prominent role in this compartment and to a lesser
extend in the coronary macrocirculation.
The toxic substances also increase the permeability of the endothelium and
make the endothelial cell hyperadhesive to leucocytes by secreting
chemotactic factors. In the formation of an atherosclerotic plaque monocytes
enter the subendothelial space through the vessel wall at the site where
the endothelium is damaged. They differentiate to macrophages, produce
free radicals and release cytokines which are chemotactic to other leucocytes.
The relaease of cytokines which have been identified to regulate the growth,
cellular differentiation and functional status of cells, and this further
enhances the atherosclerotic process31,32. Smooth muscle cells are sensitive
to these cytokines: they proliferate and produce extracellular matrix proteins
which support the formation of atherosclerotic plaques and enhance their
structural integrity33. Low density lipoprotein specifically contributes to
the formation the lipid rich core found in unstable atherosclerotic plaques34.
Stability of the atherosclerotic plaque appears an important factor since
unstable plaques are prone to rupture, leading to occlusion of the coronary
artery which may cause myocardial ischemia or even myocardial infarction.
These unstable plaques are eccentric, contain large lipid cores, contain many
macrophages and have an thin fibrous cap covering the plaque35-37. On the
other hand, stable atherosclerotic plaques contain less lipids, less
proliferated smooth muscle cells, less lymphocytes and macrophages as a
result of reduced inflammation. Generally, stable plaques do not cause
myocardial infarction but reduce the coronary blood flow which leads to
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ischemia when myocardial demand is increased. These plaques are often
responsible for anginal pain in patients with so-called “stable angina
pectoris”.
Thus, atherosclerosis causes functional and structural changes which could
disturb the blood flow in the coronary circulation. When myocardial blood
supply is insufficient to meet the myocardial demand, the myocardial cell
becomes ischemic which will affect the myocardial metabolism of the cell
and eventually its contractile function.
Glucose metabolism during ischemia
In contrast to the normal situation glucose metabolism is of considerable
importance in ischemic conditions. Ischemia develops when the coronary
circulation is not able to meet the myocardial demand. As ischemia
progresses gradual cellular metabolic changes occur, characterized by a
shift to anaerobic metabolism, a stimulation of glucose uptake, increased
glycogenolysis, an increased lactate production, and an increase in glycolytic
flux through the Krebs cycle38. Under ischemic or hypoxic conditions velocity
of glucose uptake is increased by recruitment of GLUT transporters resulting
in enhanced glucose transport, which causes an increase in glycolytic flux39.
However, when ischemia becomes more severe glucose uptake is
progressively inhibited by accumulation of ions, lactate and the damaging
effects of oxygen derived free radicals until glycolysis completely stops40,41.
The availability of glycogen for metabolism during ischemia appears to exert
a protective effect. Cellular homeostasis is better preserved and ischemic
contraction may be prevented or delayed by a sufficient amount of glycogen
available for metabolism42. In this view, intact function of ATP requiring
enzymes such as Na/K–ATPase and Ca–ATPase is considered of importance.
Viable dysfunctional myocardium
From experimental and clinical data it is known that myocardial ischemia
may be accompanied by reversible diastolic and systolic dysfunction as
shown in experiments with continuous precordial counting of the left
ventricular blood pool43,44. In case of more prolonged and severe ischemia,
myocardial dysfunction may persist even after cessation of ischemia when
myocardial blood flow has returned to normal values. This condition is called
myocardial stunning. Hibernating myocardium is also recognized as an
important pathophysiological concept in ischemic heart disease. Hibernation
was brought up by Diamond45 and Rahimtoola46 and is characterized by a
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chronic matched decrease of myocardial perfusion and contractile function.
Essential in both myocardial stunning, and hibernation is that the observed
contractile dysfunction is reversible.
Models investigating ischemic contractile dysfunction mostly describe either
the effects of stunning or hibernation. In a stunning model a brief episode
(< 30 minutes) of ischemia by total occlusion of a coronary artery is induced.
This leads to the ischemic metabolic changes described above, accompanied
by decrease in contractile function, and eventually glycolysis is shut down
of by accumulation of breakdown products. When the myocardium is
reperfused a discrepancy has been demonstrated between cardiac work and
metabolism. Cardiac work did not return to pre-ischemic values, although
glucose metabolism rapidly returned to normal47. An increased hydrogen
ion production derived from glucose metabolism during ischemia might be
responsible for the impaired cardiac work and impaired myocardial function.
The occurrence of rapid structural myocardial cellular changes in stunning
remains unclear.In conditions described as hibernation, a state of low-flow
ischemia is induced with increased glucose uptake and glycolytic flux. In
contrast to stunning, the residual flow enables the myocardium to washout
the metabolic breakdown products, preventing accumulation and cessation
of glycolysis. In this way longer periods of ischemia may be imposed to the
myocardium, thereby reducing the amount of irreversible damage to the
myocardium40. Due to chronic low-flow ischemia in hibernation both
myocardial cells and extracellular matrix exhibit distinct morphological
changes. The contractile material is gradually replaced by glycogen deposits,
together with a reduction of the sarcoplasmatic reticulum, and a variable
degree of fibrotic myocardial cells. Furthermore, numerous small
mitochondria are seen and nuclei lose their normal contours. No signs of
degenerative changes such as vacuolisation and swelling are present48-51.
Indeed, recent studies suggested that the structural changes observed in
hibernation may be the result of dedifferentiation rather than degeneration.
Similarities with fetal cardiomyocytes confirm this52,53. The structural
abnormalities seen in hibernation appear directly responsible for the
mechanical dysfunction and the delayed return of contractile function when
condition of hibernation is terminated54. Time whereafter recovery of
myocardial function is observed varies from early55 to late56 recovery and
might also depend on the duration of the hibernating period57. Moreover,
the degree of recovery is dependent on the amount of irreversible damage
measured as tissue fibrosis16,51
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In clinical practice pure situations of stunning and hibernation are rare.
More common is a situation in which patients with a severely fixed coronary
artery stenosis experience multiple periods of stunning due to a dysbalance
of an increased oxygen demand and an insufficient supply, which occurs
during exercise. Before myocardial function has recovered another period
of stunning may be experienced, resulting in prolonged and more severe
myocardial dysfunction. This situation is best described as repetitive
stunning58. Thus, it appears that stunning, hibernation and repetitive
stunning are three distinct pathophysiological conditions. However, they
show considerable overlap because: in all conditions the myocardium
exhibits contractile dysfunction, myocardial cells are viable, and finally a
certain degree of functional recovery may take place after restoration of
blood supply. Considering this, viable dysfunctional myocardium in is
probably a better term to describe these pathophysiologic processes.
Detection of viable dysfunctional myocardium is of great importance in
clinical practice, because appropriate treatment may benefit patients59,60.
Studies exploring the accuracy of various viability detection techniques for
prediction of left ventricular function recovery have been conducted61. In
these studies patients were revascularized and accuracy for prediction of
left ventricular function recovery was calculated from the observed changes
in left ventricular function after revascularization (Figure 3). However, these
studies do not resemble a clinical situation. In clinical practice, management
of patients with coronary artery disease should be directed towards
appropriate and selective revascularization of stenosed coronary arteries if
the myocardium is viable, because revascularization improves left
ventricular contractile function and prevents ischemic cardiac events62. On
the other hand, when only little viable dysfunctional myocardium is present
drug treatment is preferred. Thus, once sensitivity and specificity numbers
are explored studies investigating the performance of these techniques for
the determination of patient management (revascularization or drug
treatment) and subsequent prognosis are needed (Figure 4). Chapter 6 of
this thesis describes the very first prospective blinded randomized study
evaluating patient management and prognosis based on 13N-ammonia/18
FDG positron emission tomography (PET) and 99mTc-Sestamibi single photon










viability + viability + viability - viability -
LVF improved LVF not improved LVF improved LVF not improved
↓ ↓ ↓ ↓
TP FP FN TN
Figure 3.
Example of a study designed to explore the accuracy of a viability detection technique for
prediction of left ventricular function recovery in which all patients are revascularized.
viability +: viability detected; viability -: no viability detected; LVF: left ventricular function;





viable dysfunctional no or limited viable
myocardium dysfunctional myocardium
↓ ↓
 revascularization drug treatment
↓ ↓
prognosis assessment prognosis assessment
Figure 4.
Example of a study designed to evaluate the performance of a viability detection technique for
patient management and assessment of prognosis. This design resembles a clinical situation
where patients with sufficient viable dysfunctional myocardium are revascularized and oth-
ers with no or only limited viable dysfunctional myocardium are treated with drugs.
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POSITRON EMISSION TOMOGRAPHY IMAGING IN CORONARY
ARTERY DISEASE
Positron emission tomography (PET) imaging of radioactively labeled
substrates permits in vivo quantitative measurements of tracer uptake. A
positron emission tomography camera is able to detect two 511 keV photons
generated simultaneously by the annihilation of a positron. Acquired images
are corrected for attenuation of radiation in the tissue, and can be
reconstructed into two or three dimensional images. Tracer modeling
techniques enable the quantitative measurement of different tracers and
also myocardial function can be assessed with electrocardiographic gated
acquisition.
In this thesis measurement of global and regional myocardial perfusion
was performed with 13N-ammonia by using first pass technique and a three
compartment model described by hutchins63,64. Glucose metabolism was
measured with 18FDG using the Patlak analysis64-66. Data analysis was
performed semiautomatically and results are displayed as parametric polar
map67.
Myocardial perfusion
Myocardial perfusion with 13N-ammonia was measured under resting
conditions, during cold pressor testing and during pharmacological
vasodilatation with dipyridamole.
The cold pressor test
In the cold pressor test one of the subjects’ hands are immersed in a mixture
of water and ice for 1,5 minutes. This test is considered a non-invasive
endothelium mediated test and produces sympathetic release of
norepinephrine and epinephrine and an elevation in mean arterial
pressure68. In non-atherosclerotic coronary arteries alpha 2 and beta
adrenoceptor stimulation cause vasodilatation, and flow mediated
endothelium dependent vasodilatation via nitric oxide enhances further
vasodilatation. As a result, cold pressor testing causes vasodilatation and
improvement in myocardial perfusion in a healthy coronary circulation28,69,70.
On the other hand, cold pressor testing causes impaired vasodilatation or
even vasoconstriction of coronary arteries in patients with endothelial
dysfunction, minimal coronary artery disease, atherosclerotic coronary
arteries , and in patients with cardiovascular riskfactors (i.e. hypertension,
24
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hypercholesterolemia)28,69-73. Consequently, myocardial perfusion is
diminished in the myocardial areas supplied by these constricting arteries
when compared to a resting situation74. Exact mechanisms for
vasoconstriction remain speculative as well as mechanisms for metabolic
and neurogenic modulation, but endothelial dysfunction and defective
endothelium mediated vasodilatation are presumed to play a central role74.
Therefore, the cold pressor test is considered a non-invasive endothelium
mediated test, although its value in clinical practice has not yet been
established.
Dipyridamole Stress Test
Myocardial perfusion is also measured with dipyridamole. Dipyridamole
inhibits the breakdown of adenosine and stimulates metabolic vasodilatation
in arteriolae by an increase in cyclic-adenosinemonophosphate. According
to the dynamic flow model as described earlier, dipyridamole mediated
vasodilatation is considered integrated an measurement of endothelial
function and smooth muscle cell relaxation75. Myocardial perfusion during
dipyridamole infusion offers the possibility to measure the maximal
myocardial perfusion, assess regional perfusion abnormalities in the macro-
and microcirculation, and in combination with resting perfusion myocardial
perfusion reserve can be assessed. Myocardial perfusion imaging during
vasodilatation has been proven an accurate method to detect an impairment
of regional myocardial perfusion and correlates directly to the severity of
the coronary stenosis76. For detection of coronary artery disease maximal
perfusion is important because under resting conditions myocardial
perfusion may still be within the normal range, while maximal myocardial
perfusion is impaired in the region supplied by the stenosed coronary artery.
Myocardial glucose uptake
The amount of  uptake reflects the glucose uptake in the myocardial cell.
When 18Fluorodeoxyglucose enters the cell it is phosphorylated by
hexokinase and then trapped because phosphorylated 18Fluorodeoxyglucose
cannot be further metabolized. The uptake of 18Fluorodeoxyglucose is
dependent on the metabolic state of the myocardial cell and the circulating
levels of free fatty acids, glucose and insulin as described earlier. In this
thesis 18Fluorodeoxyglucose imaging was performed either using glucose
load technique or during euglycemic hyperinsulinemic clamp technique20.
The particular use of 18Fluorodeoxyglucose uptake in the myocardium is to
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detect viable dysfunctional myocardium. The most established method is
to detect areas with a discrepancy between a preserved or increased
18Fluorodeoxyglucose uptake (dependent on the metabolic state) and a
decreased myocardial perfusion under resting or stress conditions. These
areas are referred to as mismatch areas. On the other hand, myocardium
that exhibits a matched pattern of decreased 18Fluorodeoxyglucose uptake
and low myocardial perfusion is likely to exhibit scarred or infarcted
myocardium and is called match area48,62,77,78.
Gated acquisition
By electrocardiographic gated acquisition of positron emission tomography
data various aspects of the left ventricular function can be assessed using
sophisticated programs that calculate left ventricular ejection fraction, left
ventricular volumes, left ventricular wall motion and wall thickening79-82.
The clinical importance of detecting attenuation artifacts is not a real issue
in positron emission tomography imaging since all acquisitions are already
corrected for tissue attenuation in contrast to single photon emission
computed tomography83. However, information on cardiac function may be
valuable for a better understanding of (patho)physiology. Relations between
cardiac function, myocardial perfusion, myocardial glucose can be explored
in a noninvasive fashion. Furthermore, with the addition of functional
information positron emission tomography provides a complete cardiac work
up which may render other functional investigations such as
echocardiography and radionuclide ventriculography unnecessary. Since
positron emission tomography camera’s and the use of gated positron
emission tomography are not widespread, the exact value of gated positron
emission tomography in clinical practice needs further study.
AIM AND OUTLINE OF THE THESIS
The aim of this thesis was to explore current clinical applications of positron
emission tomography imaging in coronary atherosclerosis. First, positron
emission tomography imaging was used to monitor coronary vascular
function in various patients. To this aim we measured myocardial perfusion
reserve using dipyridamole induced vasodilatation. In addition myocardial
perfusion reserve was investigated during autonomic modulation using the
cold pressor test. Finally, the effects of chronic HMGCoA reductase inhibitor
26
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administration on coronary vascular function were investigated in
asymptomatic hypercholesterolemic subjects (chapter 2), and in patients
with established coronary artery disease (chapter 3).
A relatively new application of positron emission tomography imaging is
the assessment of left ventricular function. To explore this issue a study to
assess the accuracy of gated positron emission tomography acquisition for
measurement of left ventricular function was conducted (chapter 4).
Positron emission tomography is considered a powerful tool to detect viable
dysfunctional myocardium. In chapter 5 the performance of positron
emission tomography and various other viability detection techniques for
prediction of left ventricular function recovery are discussed. The issue of
how the various techniques determine patient management and thereby
influence prognosis in patients remains unclear. Therefore, a prospective
blinded randomized study focussing on patient management and cardiac
event free survival was conducted in a clinical setting comparing 99mTc-
Sestamibi single photon emission computed tomography with 13N-ammonia/
18FDG positron emission tomography imaging, in coronary artery disease
patients in whom revascularization was considered (chapter 6).
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